Supplemental material
Postgraduate Medicine
Volume 131, 2019 - Issue 8
Open access
6,896
Views
10
CrossRef citations to date
0
Altmetric
Clinical Focus: Cardiometabolic Conditions - Review
Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes
Rosemarie LajaraDiabetes360 Health Center, Plano, TX, USACorrespondence[email protected]
View further author information
View further author information
Pages 555-565
|
Received 15 Mar 2019, Accepted 17 Sep 2019, Published online: 03 Oct 2019
Related Research Data
Pharmacology, physiology, and mechanisms of incretin hormone action
Source:
Elsevier BV
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor
Source:
Wiley-Blackwell
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs
Source:
Ovid Technologies (Wolters Kluwer Health)
Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes
Source:
Taylor & Francis
When Metformin Fails in Type 2 Diabetes Mellitus
Source:
American Medical Association (AMA)
DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV)
Source:
Elsevier BV
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Source:
Elsevier BV
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Source:
Elsevier Science Inc
Type 2 diabetes mellitus unawareness, prevalence, trends and risk factors: National Health and Nutrition Examination Survey (NHANES) 1999–2010
Source:
SAGE Publications
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Source:
Massachusetts Medical Society
Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans
Source:
American Diabetes Association
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Source:
Massachusetts Medical Society
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
Source:
New England Journal of Medicine (NEJM/MMS)
DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV)
Source:
Elsevier BV
Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies
Source:
American Diabetes Association
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Source:
Ovid Technologies (Wolters Kluwer Health)
Cardiovascular Actions of Incretin-Based Therapies
Source:
Ovid Technologies (Wolters Kluwer Health)
GLP-1 based therapeutics: simultaneously combating T2DM and obesity.
Source:
Frontiers Media SA
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Source:
Massachusetts Medical Society
Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes
Source:
American Diabetes Association
Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience
Source:
Springer Nature
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
Source:
Elsevier BV
Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
Source:
Elsevier BV
Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
Source:
American Diabetes Association
Patient and Provider Factors Affecting Clinical Inertia in Patients With Type 2 Diabetes on Metformin Monotherapy
Source:
Elsevier BV
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Source:
New England Journal of Medicine (NEJM/MMS)
Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease
Source:
Ovid Technologies (Wolters Kluwer Health)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Source:
Massachusetts Medical Society
Effect of sodium glucose cotransporter 2 inhibitors on obstructive sleep apnea in patients with type 2 diabetes
Source:
Japan Endocrine Society
Type 2 diabetes mellitus.
Source:
Springer Science and Business Media LLC
What's So Tough About Taking Insulin? Addressing the Problem of Psychological Insulin Resistance in Type 2 Diabetes
Source:
American Diabetes Association
SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
Source:
Informa UK Limited
SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
Source:
American Diabetes Association
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Source:
New England Journal of Medicine (NEJM/MMS)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Source:
Massachusetts Medical Society
Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial
Source:
American Diabetes Association
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
Source:
American Diabetes Association
Treatment intensification for patients with type 2 diabetes and poor glycaemic control
Source:
Wiley-Blackwell
Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study
Source:
Wiley
Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Source:
Wiley
Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes
Source:
Taylor & Francis
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2019 EXECUTIVE SUMMARY
Source:
AACE Corp (American Association of Clinical Endocrinologists)
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
Source:
American Diabetes Association
A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
Source:
Informa UK Limited
DURATION-8 Randomized Controlled Trial 104-Week Results—Once-Weekly Exenatide (ExQW) plus Once-Daily Dapagliflozin (DAPA) vs. ExQW or DAPA Alone
Source:
American Diabetes Association
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Source:
Springer Science and Business Media LLC
The Burden of Treatment Failure in Type 2 Diabetes
Source:
American Diabetes Association
Insulin Action in Brain Regulates Systemic Metabolism and Brain Function
Source:
American Diabetes Association
SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM
Source:
AACE Corp (American Association of Clinical Endocrinologists)
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Source:
American Diabetes Association
Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review.
Source:
Wiley
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Source:
Massachusetts Medical Society
Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes
Source:
Informa UK Limited
6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
Source:
American Diabetes Association
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.